Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Teva
Express Scripts
Colorcon
Federal Trade Commission
QuintilesIMS
Cipla
AstraZeneca
Queensland Health
US Army

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,521,212

« Back to Dashboard

Which drugs does patent 6,521,212 protect, and when does it expire?


Patent 6,521,212 protects TYVASO and is included in one NDA. There has been one Paragraph IV challenge on Tyvaso.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 6,521,212

Title: Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
Abstract:A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
Inventor(s): Cloutier; Gilles (Chapel Hill, NC), Crow; James (Chapel Hill, NC), Wade; Michael (Chapel Hill, NC), Parker; Richard E. (Spring Hill, TN), Loyd; James E. (Nashville, TN)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:09/525,471
Patent Claim Types:
see list of patent claims
Use; Formulation; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
United Therap
TYVASO
treprostinil
SOLUTION;INHALATION022387-001Jul 30, 2009RXYesYes► Subscribe► Subscribe TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,521,212

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,756,033 Method for delivering benzindene prostaglandins by inhalation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,521,212

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1161234► Subscribe
Japan2011201907► Subscribe
Japan4819224► Subscribe
Japan2002539154► Subscribe
Spain2203449► Subscribe
European Patent Office1354588► Subscribe
European Patent Office1161234► Subscribe
Denmark1161234► Subscribe
Germany60004181► Subscribe
China1196479► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
Colorcon
Deloitte
Chinese Patent Office
Argus Health
Mallinckrodt
Healthtrust
Fish and Richardson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot